2026-05-20T03:33:33Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/124812024-11-28T15:19:31Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_19604col_20.500.12105_16939col_20.500.12105_16927col_20.500.12105_16978col_20.500.12105_19607

00925njm 22002777a 4500 dc Salvador-Martín, Sara author Kaczmarczyk, Bartosz author Álvarez, Rebeca author Navas-López, Víctor Manuel author Gallego-Fernández, Carmen author Moreno-Álvarez, Ana author Solar-Boga, Alfonso author Sánchez, Cesar author Tolin, Mar author Velasco, Marta author Muñoz-Codoceo, Rosana author Rodriguez-Martinez, Alejandro author Vayo, Concepción A. author Bossacoma, Ferrán author Pujol-Muncunill, Gemma author Fobelo, María J. author Millán-Jiménez, Antonio author Magallares, Lorena author Martínez-Ojinaga, Eva author Loverdos, Inés author Eizaguirre, Francisco J. author Blanca-García, José A. author Clemente, Susana author García-Romero, Ruth author Merino-Bohórquez, Vicente author González de Caldas, Rafael author Vázquez, Enrique author Dopazo, Ana author Sanjurjo-Sáez, María author López-Fernández, Luis A. author 2021-01-13 Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged < 18 years who started treatment with infliximab or adalimumab (29 responders and nine non-responders). Whole gene expression profiles from total RNA isolated from whole blood samples of six responders and six non-responders taken before administration of the biologic and after two weeks of therapy were analyzed using next-generation RNA sequencing. The expression of six selected genes was measured for purposes of validation in all of the 38 patients recruited using qPCR. Results: Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or <−0.6 and p value < 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21, and 1.08, respectively, p value < 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. Pharmaceutics. 2021; 13(1):77 10.3390/pharmaceutics13010077 1999-4923 Pharmaceutics http://hdl.handle.net/10668/16953 33429950 http://hdl.handle.net/20.500.12105/12481 Biomarker Gene Expression Infliximab Adalimumab Ulcerative Colitis Crohn Disease Inflammatory Bowel Disease Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease